Recursion Pharmaceuticals (RXRX) Other Working Capital Changes (2020 - 2026)

Recursion Pharmaceuticals (RXRX) has 7 years of Other Working Capital Changes data on file, last reported at -$2.2 million in Q1 2026.

• Quarterly Other Working Capital Changes rose 76.97% year-over-year to -$2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$29.3 million (down 21.17% YoY) and the FY2025 annual result came in at -$36.8 million, down 31.15% from the prior year.
• Other Working Capital Changes improved to -$2.2 million in Q1 2026, from -$6.8 million in the prior quarter.
• In the past five years, Other Working Capital Changes ranged from a high of $7.6 million in Q1 2022 to a low of -$25.4 million in Q2 2025.
• A 5-year average of -$2.0 million and a median of $317000.0 in 2023 frame the typical range for Other Working Capital Changes.
• The widest YoY moves for Other Working Capital Changes: up 5888.04% in 2022, down 5800.52% in 2022.
• Tracing RXRX's Other Working Capital Changes over 5 years: stood at -$13.7 million in 2022, then soared by 43.58% to -$7.7 million in 2023, then climbed by 26.59% to -$5.7 million in 2024, then dropped by 19.3% to -$6.8 million in 2025, then soared by 66.73% to -$2.2 million in 2026.
• The last three Other Working Capital Changes figures came in at -$2.2 million (Q1 2026), -$6.8 million (Q4 2025), and -$6.6 million (Q3 2025), per Business Quant data.